Overview

Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects

Status:
Active, not recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, single-center study of XNW4107 and imipenem/cilastatin administered intravenously.
Phase:
Phase 1
Details
Lead Sponsor:
Sinovent Pty Ltd.
Treatments:
Cilastatin
Imipenem